Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year · Ends Nov 29, 19:00 ET

Black Friday $299.50 → $149.00 Ends Nov 29, 19:00 ET Black Friday $299.50 → $149.00 Ends Nov 29, 19:00 ET Black Friday $299.50 → $149.00 Ends Nov 29, 19:00 ET Black Friday $299.50 → $149.00 Ends Nov 29, 19:00 ET Black Friday $299.50 → $149.00 Ends Nov 29, 19:00 ET

ENSC

Ensysce Biosciences Inc

0.3600

Nov 10 • 3:59 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: HRTX AZR LPCN QUIT CING VTGN TNXP KTTA MNOV SILO

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	7.00M
Enterprise Value	6.19M
Income	-12.62M
Sales	4.50M
Book/sh	-0.05
Cash/sh	0.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Feb 26, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	1.56
P/B	-
P/C	10.29
P/FCF	-
EV/EBITDA	-
EV/Sales	1.38
Quick Ratio	0.60
Current Ratio	0.60
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-2.76
EPS next Y	-0.06
EPS next Q	-0.12
EPS this Y	84.92%
EPS next Y	90.00%
EPS next 5Y	72.81%
EPS past 3/5Y	87.61% -
Sales past 3/5Y	26.16% 5.21%
EPS Y/Y TTM	27.41%
Sales Y/Y TTM	-39.29%
EPS Q/Q	74.95%
Sales Q/Q	-15.10%
Earnings	Aug 19
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	4.72%
Insider Trans	-
Inst Own	5.36%
Inst Trans	5.68%
ROA	-295.93%
ROE	-968.33%
ROIC	-
Gross Margin	-
Oper. Margin	-281.32%
Profit Margin	-280.48%
SMA20	-19.39%
SMA50	-19.63%
SMA200	-12.96%
Trades

Shs Outstand	19.46M
Shs Float	18.54M
Short Float	0.48%
Short Ratio	0.09
Short Interest	0.09M
52W High	2.17 -83.41%
52W Low	0.23 56.52%
Volatility	13.50% 11.24%
ATR (14)	0.05
RSI (14)	36.62
Beta	1.10
Rel Volume	0.00
Avg Volume	1.01M
Volume	0

Perf Week	-4.69%
Perf Month	-35.24%
Perf Quarter	-9.71%
Perf Half Y	13.74%
Perf YTD	-60.87%
Perf Year	-82.27%
Perf 3Y	-97.00%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	1.00
Target Price	5.12
Prev Close	0.36
Price	0.36
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$5.12

Implied Upside

+1,322.2%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Initiated	CCantor Fitzgerald	Overweight	$2	+455.6%

Oct-21-26 08:00AM	Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai (ACCESSWIRE)
Sep-24-26 08:00AM	Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA (ACCESSWIRE)
Sep-15-26 09:15AM	Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation (ACCESSWIRE) -6.19%
Sep-14-26 08:00AM	Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs (ACCESSWIRE)
Sep-02-26 08:30AM	Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation (ACCESSWIRE) +14.09%
08:30AM	Loading…
Aug-31-26 08:30AM	Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study (ACCESSWIRE)
Aug-20-26 08:00AM	Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium (ACCESSWIRE)
Aug-13-26 04:15PM	Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights (ACCESSWIRE) -12.59% +14.75%
Aug-06-26 10:50AM	Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing (InvestorsHub) +44.83%
08:00AM	Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing (ACCESSWIRE)
Jul-14-26 10:45AM	Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development (InvestorsHub) +6.17%
08:00AM	Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant (ACCESSWIRE)
Jun-26-26 08:00AM	Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study (ACCESSWIRE) +6.33%
May-15-26 04:15PM	Ensysce Biosciences Reports First Quarter 2026 Financial Results (ACCESSWIRE) +13.17%
May-12-26 08:00AM	Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology (ACCESSWIRE) -17.15%
10:30AM	Loading…
May-11-26 10:30AM	BC-Most Active Stocks (Associated Press) +9.08%
May-08-26 08:00AM	Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam (ACCESSWIRE) -5.35%
Apr-16-26 08:00AM	Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study (ACCESSWIRE)
Apr-07-26 08:00AM	Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs (ACCESSWIRE)
Mar-30-26 04:50PM	Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results (ACCESSWIRE)
Mar-04-26 08:45AM	Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans (ACCESSWIRE)
Mar-03-26 08:00AM	Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology (ACCESSWIRE) -15.00%
Feb-27-26 12:10PM	Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review (Benzinga) +57.77%
Feb-25-26 08:00AM	Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value (ACCESSWIRE)
Feb-23-26 08:00AM	Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events (ACCESSWIRE) -6.62%
Jan-28-26 08:00AM	Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain (ACCESSWIRE) -6.92%
Jan-21-26 08:00AM	Ensysce Biosciences Expands Global Opioid Patent Portfolio (ACCESSWIRE)
Jan-08-26 08:00AM	Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection (ACCESSWIRE)
Jan-05-26 08:00AM	Ensysce Biosciences Issues Annual Shareholder Letter (ACCESSWIRE) +10.64%
Dec-09-25 08:00AM	Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid (ACCESSWIRE) -11.25%
08:00AM	Loading…
Dec-02-25 08:00AM	Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology (ACCESSWIRE)
Nov-20-25 08:00AM	Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach (ACCESSWIRE) -12.02%
Nov-17-25 08:05AM	Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs (ACCESSWIRE)
Nov-14-25 04:15PM	Ensysce Biosciences Reports Third Quarter 2025 Financial Results (ACCESSWIRE)
Oct-10-25 08:00AM	Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 (ACCESSWIRE)
Sep-04-25 08:00AM	Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium (ACCESSWIRE)
Aug-19-25 08:00AM	Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 (ACCESSWIRE)
Aug-15-25 08:00AM	Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) (GlobeNewswire)
Aug-13-25 04:15PM	Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates (ACCESSWIRE)
Jul-31-25 08:00AM	Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback (ACCESSWIRE)
Jul-16-25 08:00AM	Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse (ACCESSWIRE)
Jun-24-25 08:00AM	Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 (ACCESSWIRE)
Jun-11-25 08:00AM	Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025 (ACCESSWIRE)
Jun-04-25 08:00AM	Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection (ACCESSWIRE)
May-13-25 04:15PM	Ensysce Biosciences Reports First Quarter 2025 Financial Results (ACCESSWIRE) -5.48% +11.59%
May-12-25 08:00AM	Ensysce Biosciences Bolsters Management Team with Regulatory Expert (ACCESSWIRE)
Apr-24-25 04:15PM	Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds (ACCESSWIRE) -9.81%
Apr-23-25 04:41PM	Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds (ACCESSWIRE) +96.26%
08:00AM	Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder (ACCESSWIRE)
Apr-15-25 08:00AM	Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study (ACCESSWIRE) +14.29%
Mar-31-25 08:00AM	Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -21.23%
Mar-18-25 08:00AM	Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain (ACCESSWIRE)
Mar-13-25 08:00AM	Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) (GlobeNewswire) -14.45%
Mar-10-25 04:15PM	Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results (ACCESSWIRE)
Mar-05-25 08:00AM	Ensysce Biosciences to Participate in the 37th Annual ROTH Conference (ACCESSWIRE) -5.62%
Mar-03-25 09:43AM	Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids (PR Newswire)
Feb-05-25 08:00AM	Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment (ACCESSWIRE)
Jan-22-25 08:00AM	Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR (ACCESSWIRE)
Jan-08-25 08:00AM	Ensysce Biosciences Issues Annual Shareholder Letter (ACCESSWIRE)
Dec-23-24 08:00AM	Ensysce Biosciences Regains Full Compliance with Nasdaq (ACCESSWIRE)
Dec-10-24 08:00AM	Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product (ACCESSWIRE)
Dec-04-24 08:00AM	Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR (ACCESS Newswire) -8.04%
Dec-03-24 04:15PM	Ensysce Biosciences Announces 1-for-15 Reverse Stock Split (ACCESSWIRE) -6.78%
Nov-26-24 08:00AM	Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial (ACCESSWIRE) +14.45%
Nov-12-24 04:15PM	Ensysce Biosciences Reports Third Quarter 2024 Financial Results (ACCESSWIRE) +5.10%
Nov-07-24 08:00AM	Ensysce Biosciences Receives Positive Nasdaq Listing Determination (ACCESSWIRE) +26.42%
Oct-08-24 08:00AM	Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit (ACCESSWIRE) -14.87%
Oct-02-24 08:00AM	Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries (ACCESSWIRE)
Sep-27-24 04:30PM	Ensysce Biosciences Receives Notice from Nasdaq (ACCESSWIRE) +5.53% -16.67%
Sep-24-24 08:00AM	Ensysce Biosciences Presenting at Upcoming Meetings (ACCESSWIRE)
Sep-19-24 07:00AM	Ensysce Biosciences Submits Phase 3 Protocol to the FDA (ACCESSWIRE)
Sep-13-24 08:00AM	Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 (ACCESSWIRE)
Aug-29-24 08:00AM	Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants (ACCESSWIRE) -34.67%
08:00AM	Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) (GlobeNewswire)
Aug-27-24 02:30PM	Ensysce Biosciences Announces IRB Approval for Key MPAR Study (ACCESSWIRE) +47.06%
08:00AM	Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection (ACCESSWIRE)
Aug-23-24 08:00AM	Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) (GlobeNewswire) +7.54%
Aug-14-24 04:15PM	Ensysce Biosciences Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Aug-08-24 08:25AM	Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium (ACCESSWIRE)
Jul-23-24 08:00AM	Ensysce Biosciences Provides Mid-Year 2024 Update (ACCESSWIRE)
Jul-09-24 08:00AM	Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset (ACCESSWIRE) +5.61%
Jun-27-24 08:00AM	Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting (ACCESSWIRE)
Jun-25-24 08:00AM	Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate (ACCESSWIRE)
Jun-24-24 10:52AM	ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Jun-06-24 08:00AM	Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program (ACCESSWIRE)
Jun-03-24 08:00AM	Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting (ACCESSWIRE)
May-28-24 08:00AM	Ensysce Biosciences Regains Compliance with Nasdaq (ACCESSWIRE)
May-20-24 08:00AM	Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform (ACCESSWIRE) +18.43%
May-13-24 08:00AM	Ensysce Biosciences Reports First Quarter 2024 Financial Results (ACCESSWIRE) +11.64%
Apr-25-24 08:00AM	Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine (ACCESSWIRE)
Apr-19-24 08:00AM	Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published (ACCESSWIRE)
Apr-09-24 08:00AM	Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (ACCESSWIRE)
Mar-18-24 10:53AM	ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Mar-15-24 08:00AM	Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results (ACCESSWIRE) +5.81%
Feb-27-24 08:00AM	Ensysce Biosciences Receives Positive Nasdaq Listing Determination (ACCESSWIRE)
Feb-21-24 08:00AM	Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection (ACCESSWIRE)
Feb-15-24 08:00AM	Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript (ACCESSWIRE)
Feb-13-24 08:00AM	Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds (ACCESSWIRE) -24.56%
Feb-06-24 08:00AM	Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference (ACCESSWIRE) -6.00%
Jan-31-24 08:00AM	Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain (ACCESSWIRE) +12.50%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOWER BOB G	Director	Apr 23 '26	Buy	0.48	508,614	246,169	516,740	Aug 18 06:06 AM
GOWER BOB G	Director	Aug 07 '26	Buy	0.49	400,000	198,000	916,740	Aug 18 06:06 AM

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

CEO & DirectorDr. D. Lynn Kirkpatrick Ph.D.

CFOMr. David C. Humphrey CPA

Chief Commercial OfficerMr. Geoffrey Birkett

President & DirectorMr. James Morrison

Chairman of Clinical Advisory Board & Chief Medical OfficerDr. William K. Schmidt Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ENSC

Ensysce Biosciences Inc

Upgrade your Finviz experience

All the Features.
Half the Price.